News

National Institute for Health and Care Excellence6y
Lenvatinib for untreated advanced hepatocellular carcinoma
The daily dose of lenvatinib in the summary of product characteristics is 8 mg (2×4 mg capsules) given orally for patients who weigh less than 60 kg, and 12 mg (3×4 mg capsules) orally for patients ...
Business Insider6y
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
WOODCLIFF LAKE, N.J. and KENILWORTH, N.J., Aug. 16, 2018 /PRNewswire/ -- Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United Stat ...
National Institute for Health and Care Excellence7y
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
2.3 The list price of lenvatinib is £1,437.00 per 30‑capsule pack (4 mg and 10 mg). The list price of everolimus is £2,250.00 per 30‑tablet pack of 5 mg everolimus. The company has agreed a patient ...
Cancer Research UK2y
A trial of pembrolizumab and lenvatinib for liver cancer (PRIMER-1)
Each 3 week period is a cycle of treatment. You have 2 cycles of treatment before surgery. Lenvatinib is a capsule. You take the capsules once a day every day for 6 weeks before surgery. Your doctor ...
Yahoo Finance3y
Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia
“We’re pleased to announce the approval of Lenvima ® (lenvatinib) in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable h ...